Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males

被引:41
|
作者
Stass, H [1 ]
Kubitza, D [1 ]
Möller, JG [1 ]
Delesen, H [1 ]
机构
[1] Bayer AG, Pharma Res Ctr, ICP, D-42096 Wuppertal, Germany
关键词
activated charcoal; moxifloxacin; pharmacokinetics;
D O I
10.1111/j.1365-2125.2005.02357.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concentrations of moxifloxacin in the event of overdose. Methods Nine healthy males, mean age 34 years (range 23-45 years) participated in a single centre, randomized, nonplacebo-controlled, three way crossover study. The pharmacokinetics of moxifloxacin in plasma and urine were determined for up to 96 h following a 400 mg single dose randomly administered on three separate occasions with a minimum washout phase of 1 week. Treatment A was 400 mg moxifloxacin IV as a 1 h infusion, treatment B was 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g directly before the start of the infusion, 5 g immediately after the end of the infusion, and 10 g at 2, 4 and 8 h after the start of the infusion), treatment C was 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4 and 8 h after drug administration). The subjects underwent a series of clinical and laboratory tests. Results Single 400 mg doses of moxifloxacin (PO and/or IV) were safe and well tolerated. The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h). Concurrently peak concentrations were lowered C-max = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05). Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C. Terminal half-lives were not affected. The kinetics of urinary excretion corroborated these findings. Conclusions The results of this study show that moxifloxacin undergoes pronounced enteric recycling after systemic uptake. In addition, these findings confirm that activated charcoal may be useful in treating moxifloxacin overdose by preventing its absorption.
引用
收藏
页码:536 / 541
页数:6
相关论文
共 50 条
  • [1] Effect of Food on the Pharmacokinetics of a Single Oral Dose of Moxifloxacin 400mg in Healthy Male Volunteers
    John Lettieri
    Ramon Vargas
    Vipin Agarwal
    Patrick Liu
    Clinical Pharmacokinetics, 2001, 40 : 19 - 25
  • [2] Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers
    Wagenlehner, F. M. E.
    Kees, F.
    Weidner, W.
    Wagenlehner, C.
    Naber, K. G.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 (01) : 21 - 26
  • [3] Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects
    Setoyama, T
    Laurent, A
    Humphries, T
    Hasegawa, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2005, 43 (01) : 37 - 42
  • [4] Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers
    Crevoisier, C
    Delisle, MC
    Joseph, I
    Foletti, G
    EUROPEAN NEUROLOGY, 2003, 49 (03) : 173 - 177
  • [5] Effect of Probenecid on the Kinetics of a Single Oral 400mg Dose of Moxifloxacin in Healthy Male Volunteers
    Heino Stass
    Richard Sachse
    Clinical Pharmacokinetics, 2001, 40 : 71 - 76
  • [6] PHARMACOKINETICS AND METABOLISM OF DILTIAZEM IN HEALTHY-MALES AND FEMALES FOLLOWING A SINGLE ORAL DOSE
    YEUNG, PKF
    PRESCOTT, C
    HADDAD, C
    MONTAGUE, TJ
    MCGREGOR, C
    QUILLIAM, MA
    XEI, M
    LI, R
    FARMER, P
    KLASSEN, GA
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (02) : 199 - 206
  • [7] Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers
    Heino Stass
    Michael-Friedrich Böttcher
    Klaus Ochmann
    Clinical Pharmacokinetics, 2001, 40 : 39 - 48
  • [8] Apixaban Single-Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration
    Frost, Charles
    Garonzik, Samira
    Shenker, Andrew
    Barrett, Yu Chen
    LaCreta, Frank
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (09): : 974 - 984
  • [9] Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose
    Wacke, Rainer
    Foerster, Sven
    Adam, Ulrich
    Mundkowski, Ralf G.
    Klar, Ernst
    Hopt, Ulrich T.
    Drewelow, Bernd
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (05) : 994 - 999
  • [10] PHARMACOKINETICS OF PANTOPRAZOLE FOLLOWING SINGLE INTRAVENOUS AND ORAL-ADMINISTRATION TO HEALTHY MALE-SUBJECTS
    PUE, MA
    LAROCHE, J
    MEINEKE, I
    DEMEY, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (06) : 575 - 578